Clinical trial
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal…
NCT00003073 · Pacira Pharmaceuticals, Inc, Industry · Unknown status
Key facts
| NCT number | NCT00003073 |
|---|---|
| Title | Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors |
| Official title | A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies |
| Lead sponsor | Pacira Pharmaceuticals, Inc, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | liposomal cytarabine |
| Enrollment | 15 |
| Start date | Feb 1, 1997 |
| First posted | Feb 6, 2004 |
| Last update posted | Mar 23, 2010 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: